Sermorelin
Last reviewed September 26, 2026
Sermorelin is a research compound.
- Route studied
- Subcutaneous
- Receptor class
- GHRH-R
- Research status
- Approved analog
Published reviews describe the clinical use of Sermorelin in the diagnosis and treatment of children with idiopathic growth hormone deficiency, and it continues to be discussed in research on adult-onset growth hormone insufficiency and other areas.
What the research covers
What research examines
- Diagnosis of idiopathic growth hormone deficiency in children
- Treatment of idiopathic growth hormone deficiency in children
- Adult-onset growth hormone insufficiency
- Recurrent glioma (exploratory research)
- Analytical detection and serum stability of GHRH analogs
- PEGylation of GHRH analogues
Reported effects in studies
- Adverse events are not summarized in the cited studies
- Human safety data outside pediatric growth hormone deficiency research are limited
- Synthetic GHRH analogs are targets of anti-doping detection methods
- Enzymatic and serum degradation of GHRH-related peptides has been characterized
What research protocols have used
Research protocols have used 200–500 mcg per administration, 5 days per week (evening), in 12-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorCited research
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999 · PubMed 18031173
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging · 2006 · PubMed 18046908
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine · 2021 · PubMed 33842627
- Advances in the detection of growth hormone releasing hormone synthetic analogs.
Drug testing and analysis · 2021 · PubMed 34665524
- In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.
Biomedical chromatography : BMC · 2023 · PubMed 37688464
Questions about Sermorelin
Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) that targets the GHRH receptor (GHRH-R). It has been reviewed in the literature for its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency, and it has been discussed as an approach to adult-onset growth hormone insufficiency. CoreX supplies Sermorelin for laboratory research use only.
Sermorelin is classed as a GHRH receptor (GHRH-R) agonist. It binds the receptor through which endogenous growth hormone-releasing hormone signals the pituitary to release growth hormone. Because it acts upstream of growth hormone rather than supplying the hormone itself, it has been discussed in research as an alternative approach to studying growth hormone insufficiency. Research protocols have typically used the subcutaneous route.
The main body of published work concerns the diagnosis and treatment of idiopathic growth hormone deficiency in children, along with commentary on adult-onset growth hormone insufficiency. Exploratory research has examined Sermorelin as a potential agent in recurrent glioma. Analytical studies have addressed detection of synthetic GHRH analogs, their enzymatic and serum stability, and PEGylation of GHRH analogues as a strategy to modify their properties.
Adverse events are not summarized in the cited studies, and human safety data outside pediatric growth hormone deficiency research are limited. Reviews of peptide use in sport and bodybuilding discuss GHRH-related compounds in the context of doping, and synthetic GHRH analogs are targets of anti-doping detection methods. Stability studies have characterized how GHRH-related peptides degrade in enzymatic and serum conditions, which is relevant to sample handling in laboratory work.
Research protocols have used 200–500 mcg per administration, 5 days per week in the evening, in 12-week blocks followed by 4 weeks off, via the subcutaneous route. These figures describe what published or reported research protocols have used and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference.
Ask about Sermorelin
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
Sermorelin at CoreX
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Longevity
$109.00









